Drug intelligence / Profile preview

anakinra + zinc

Development stage: Discontinued
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Subcutaneous, Oral

Overview

Anakinra plus zinc is a combination therapy consisting of anakinra, an interleukin-1 (IL-1) receptor antagonist, and oral zinc supplementation. Anakinra works by blocking the pro-inflammatory effects of IL-1, which is believed to play a role in the pathogenesis of alcohol-associated hepatitis. Zinc supplementation was included to potentially address nutritional deficiencies and support liver function. This combination has been studied for the treatment of severe alcohol-associated hepatitis.

Targets

IL1R1 (Interleukin-1 Receptor Type 1)

Beyond the preview

Go deeper on anakinra + zinc.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anakinra + zinc.

Explore the full profile